SHARE - Symbicort and Health Economics in a Real Life Evaluation
Phase 3
Completed
- Conditions
- Asthma
- Registration Number
- NCT00259766
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1970
Inclusion Criteria
- Signed informed consent,
- asthma,
- previously treated with glucocorticosteroids and B2-agonist
Exclusion Criteria
- History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities
- Secondary Outcome Measures
Name Time Method Number of days patients or assistant persons are absent from work due to patient's asthma Number of exacerbations and treatment failures
Trial Locations
- Locations (3)
Reseearch Site
🇸🇪Perstorp, Sweden
Research Site
🇸🇪Örebro, Sweden
Research site
🇸🇪Ödeshög, Sweden